

**The YODA Project**  
**Research Proposal Due Diligence Assessment**

<b>Part 1: General Information</b>	
<b>YODA Project (Protocol) ID:</b>	2021-4844
<b>Date:</b>	12 January 2022
<b>Product Name:</b>	Esketamine
<b>Therapeutic Area:</b>	Neuroscience
<b>Product Class:</b>	NMDA receptor antagonist
<b>Condition(s) Studied:</b>	Treatment Resistant Depression Major Depressive Disorder
<b>Protocol Number(s) and Title(s):</b>	<p><b>NCT02417064 - ESKETINTRD3001</b> - A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression</p> <p><b>NCT02418585 - ESKETINTRD3002</b> - A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression</p> <p><b>NCT02422186 - ESKETINTRD3005</b> - A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression</p> <p><b>NCT02497287 - ESKETINTRD3004</b> - An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression</p> <p><b>NCT02493868 - ESKETINTRD3003</b> - A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression</p> <p><b>NCT01998958 - ESKETINTRD2003</b> - A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in TreatmentResistant Depression (SYNAPSE)</p> <p><b>NCT02133001 - ESKETINSUI2001</b> - A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Who Are Assessed to be at Imminent Risk for Suicide</p> <p><b>NCT03039192 - 54135419SUI3001</b> - A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide</p> <p><b>NCT03097133 - 54135419SUI3002</b> - A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care</p>

## The YODA Project

### Research Proposal Due Diligence Assessment

	<p>for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide</p> <p><b>NCT02918318 - 54135419TRD2005</b> - A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression</p> <p><b>NCT01627782 - KETIVTRD2002</b> - A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression</p> <p><b>NCT01640080 - ESKETIVTRD2001</b> - A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects With Treatment-Resistant Depression</p>
<b>Part 2: Data Availability</b>	
<b>Question:</b>	<b>Response:</b>
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments: N/A	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments: N/A	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments: N/A	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments: N/A	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments: N/A	
<b>Part 3: Data Availability Summary</b>	
Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.	Yes
<b>Part 4: Proposal Review</b>	
<b>Question:</b>	<b>Response:</b>
Summary-level CSR data is appropriate for the proposed analysis.	Yes
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No*
Comments:	*some of the objectives (but not all) have been addressed in publications (e.g. The International Journal of Neuropsychopharmacology).